Description
Novoseven RT 5mg Online
Novoseven RT (FACTOR VIIa) (fak tir VIIa, ree kom bi nant) helps to prevent or control bleeding in patients with hemophilia A or hemophilia B who have clotting factor inhibitors. This medicine may also be used to treat bleeding in patients with factor VII deficiency or in select patients who have other types of bleeding problems.
NovoSeven is used to treat and prevent bleeding episodes in patients with Hemophilia A or B who have formed antibodies against other clotting proteins (eg, Factor VIII or Factor IX) that help bleeding to stop. It is also used to treat or prevent bleeding in patients with acquired hemophilia, congenital Factor VII deficiency, or Glanzmann’s thrombasthenia (a bleeding disorder that is caused by a blood abnormality) that has been treated with platelet transfusions but did not work well.
NovoSeven contains activated recombinant coagulation factor VII. The mechanism of action includes the binding of factor VIIa to exposed tissue factors. This complex activates factor IX into factor IXa and factor X into factor Xa, leading to the initial conversion of small amounts of prothrombin into thrombin. Thrombin leads to the activation of platelets and factors V and VIII at the site of injury and to the formation of the haemostatic plug by converting fibrinogen into fibrin. Pharmacological doses of NovoSeven activate factor X directly on the surface of activated platelets, localized to the site of injury, independently of tissue factor. This results in the conversion of prothrombin into large amounts of thrombin independently of tissue factor.
